Welcome to our dedicated page for Tempest Therapeutics SEC filings (Ticker: TPST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempest Therapeutics, Inc. (NASDAQ: TPST) SEC filings page on Stock Titan provides investors with direct access to the company’s regulatory disclosures, along with AI-assisted context. Tempest is a clinical-stage biotechnology company headquartered in Brisbane, California, developing small molecule and cell-based therapeutics with tumor-targeted and immune-mediated mechanisms to fight cancer.
Through this page, users can review Tempest’s Form 8-K current reports, which the company uses to announce material events such as equity financings, asset purchase agreements, and leadership changes. For example, Tempest has filed 8-Ks describing registered direct offerings of common stock and concurrent private placements of warrants, as well as an asset purchase agreement to acquire dual-targeting CAR T-cell therapy programs from Factor Bioscience affiliates.
Investors can also use this section to locate Tempest’s periodic reports, such as Forms 10-Q and 10-K, which include detailed financial statements, risk factor discussions, and management’s analysis of its clinical-stage oncology pipeline and capital resources. These filings complement the company’s press releases on quarterly financial results and business updates.
Stock Titan enhances Tempest’s SEC filings with AI-powered summaries that highlight key terms, financing structures, and transaction conditions, helping readers quickly understand complex documents without replacing the full text. The platform also surfaces information on equity issuances, warrant terms, and other securities-related disclosures reported under unregistered sales of equity securities. Real-time updates from the EDGAR system ensure that new TPST filings, including future 10-K, 10-Q, and 8-K reports, appear promptly, allowing investors to track Tempest’s regulatory history and ongoing corporate developments in one place.
Tempest Therapeutics (TPST) filed its Q3 2025 report, highlighting constrained liquidity and a strategic review. Cash and cash equivalents were $7.5 million with total assets of $17.1 million and stockholders’ equity of $6.3 million as of September 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern, noting existing cash is expected to fund operations for less than 12 months from the financial statement issuance date.
Quarterly net loss was $3.5 million versus $10.6 million a year earlier, driven by a sharp reduction in research and development to $0.6 million from $7.6 million amid the workforce reduction and paused programs during the strategic review. General and administrative expenses were $3.0 million, roughly flat year over year.
Financing actions included a registered direct offering delivering net proceeds of $4.1 million and ATM sales totaling $2.8 million year-to-date. The Oxford term loan was fully repaid for $3.5 million in April, releasing all liens. A one-for-thirteen reverse stock split was effected in April. Programs include amezalpat, cleared to begin a pivotal Phase 3 in HCC with FDA Fast Track and Orphan Drug designations, and TPST-1495, slated for an NCI-funded Phase 2 in FAP.
Tempest Therapeutics (TPST) furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the quarter ended September 30, 2025 and other business highlights. The press release is attached as Exhibit 99.1 and incorporated by reference. The information is furnished, not filed, under the Exchange Act.
The filing also includes Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.
Versant-affiliated funds filed Amendment No.6 to their Schedule 13D for Tempest Therapeutics (TPST) to update reported holdings after the issuer sold additional shares, causing dilution. The Amendment lists holdings including 162,972 shares (3.7%) held by Versant Vantage II, 90,084 shares (2.0%) held by Versant Venture Capital IV, 16,149 shares (0.4%) held by Versant Venture Capital VI, and 567 shares (0.0%) held by Versant Side Fund IV, with percentages based on 4,440,161 shares outstanding as of August 4, 2025.
The filing notes a one-for-thirteen reverse stock split effective April 8, 2025, states the aggregate ownership reported by the Reporting Persons decreased by over 1% due to the Issuer's additional share sales, and expressly disclaims status as a "group".
Tempest Therapeutics is a clinical-stage oncology company advancing two lead programs while conducting a strategic review to extend limited cash resources. The lead candidate, amezalpat, is positioned to begin a pivotal Phase 3 trial in first-line hepatocellular carcinoma and has received regulatory momentum including FDA Orphan Drug and Fast Track designations, a favorable end-of-Phase 2 meeting, and agency clearances to proceed in the U.S. and China; the company also reported EMA Orphan Drug designation. The second program, TPST-1495, received FDA authorization for an NCI-supported Phase 2 study in FAP and an FDA Orphan Drug designation.
Financially, Tempest reported $14.3 million in cash and cash equivalents and an accumulated deficit of $225.8 million. Net loss was $18.7 million for the six months ended June 30, 2025. The company expects existing cash to fund operations for less than 12 months, raising substantial doubt about its ability to continue as a going concern. In April 2025 Tempest launched a strategic alternatives process, reduced headcount (21 of 26 employees), transitioned key executives to consulting arrangements, completed a registered direct offering that raised net proceeds of ~$4.1 million, sold ~$2.8 million of stock via its ATM program year-to-date, and repaid its term loan in April 2025.
Tempest Therapeutics reported that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to this report as Exhibit 99.1. This Form 8-K indicates the company is furnishing the press release rather than "filing" it, meaning the release is provided for investor information in this report but is not subject to the liabilities of being formally filed or automatically incorporated by reference in other Securities Act filings. The 8-K itself does not include the numerical financial statements; those figures are contained in the attached press release.